Loading data for IRD — first visit, this takes a few seconds.

アラート

Opus Genetics Inc. (IRD)

NasdaqCM: IRD · リアルタイム株価 · USD

3.65

+0.04 (1.11%)

終値時点： Aug 19, 2026, 10:40 AM

1.11% (1D)

買気配	2.68
時価総額	303.66M
売上高（TTM）	9.86M
純利益（TTM）	-107.61M
ベータ	0.58
EPS（TTM）	-1.31
PER（TTM）	n/a
予想PER	-5.15
PBR（TTM）	-23.25
PSR（TTM）	30.81
Earnings Date	Nov 11, 2026

売気配	4.63
出来高	603,428
平均出来高（20日）	952,954
始値	3.60
前日終値	3.61
当日レンジ	3.55 - 3.75
52週レンジ	1.10 - 5.81
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

IRDについて

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The compa...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Nov 10, 2005

従業員数 27

上場取引所 NasdaqCM

ティッカー IRD

ウェブサイト https://opusgtx.com

企業情報の全文

業績

2025年のOpus Geneticsの売上高は14.2Mで、前年の10.99Mから29.15%の増加でした。利益は-49.59Mで、-13.8%の減少でした。

財務諸表

決算サプライズ

Opus GeneticsはAug 6, 2026に四半期決算を発表しました：

売上高は $755K で、予想を下回りました $0, うち -73.80% の前年比減少.

EPSは -0.08 で、予想を上回りました 0.08, うち 33.33% の前年比増加にあたります.

次回決算発表

Opus Genetics Inc.の決算発表予定日は Nov 11, 2026, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1週間前 · Zacks

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1か月前 · Insider Monkey

RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup

Opus Genetics, Inc. (NASDAQ:IRD), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. A bullish new analyst call and a broadening gene therapy pipel...

2か月前 · Insider Monkey

Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target

While Opus Genetics, Inc. (NASDAQ:IRD) has gained 100.50% year-to-date, analysts continue to see 148.10% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. Fresh cover...

2か月前 · MarketBeat

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within t...

3か月前 · Zacks

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

2ページ中1ページ

Opus Genetics Inc. (IRD)